Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 17/20 | 0.44 |
| ▸ | S1PR3 | Q99500 | 12/20 | 0.44 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16301206 | 0.91 | S1PR1 (0.46) | S1PR1S1PR3CYP2C8CYP2C9HCAR2 | |
| SCHEMBL16301190 | 0.86 | S1PR1 (0.47) | S1PR1S1PR3CYP2C8CYP2C9HCAR2 | |
| SCHEMBL11971233 | 0.85 | S1PR1 (0.53) | S1PR1S1PR3CYP2C8CYP3A4KCNH2 | |
| SCHEMBL16301177 | 0.83 | CYP1A2 (0.50) | S1PR1S1PR3CYP2C9CYP3A4 | |
| SCHEMBL11971191 | 0.81 | S1PR1 (0.62) | S1PR1S1PR3CYP2C8CYP3A4KCNH2 | |
| SCHEMBL16301178 | 0.80 | S1PR1 (0.47) | S1PR1S1PR3CYP2C8CYP3A4KCNH2 | |
| SCHEMBL1806740 | 0.76 | S1PR1 (0.55) | S1PR1S1PR3CYP2C8CYP3A4KCNH2 | |
| SCHEMBL16301180 | 0.72 | S1PR1 (0.46) | S1PR1S1PR3 | |
| SCHEMBL1806881 | 0.72 | S1PR1 (0.64) | S1PR1S1PR3CYP2C8CYP3A4KCNH2 | |
| SCHEMBL1808515 | 0.70 | S1PR1 (0.57) | S1PR1S1PR3CYP2C8CYP3A4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9216972-B2 | Tricyclic heterocyclic compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-12-22 | — | — | US | disclosed |
| US-20120214767-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2012-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214767-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS | S1PR1, S1PR3, TBXA2R | S1PR1 1/4885S1PR3 2/4885CYP2C8 2879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.